
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc's focus on developing IMVT-1402 as an FcRn inhibitor demonstrates significant promise in addressing autoimmune diseases, particularly given the sustained reduction in TRAb levels noted during off-treatment periods. The effective responder rate of 81% in a population previously unresponsive to anti-thyroid drugs, along with comparable results to the active treatment period, underscores the potential durability and disease-modifying capabilities of their treatment. These compelling clinical outcomes bolster the positive outlook for Immunovant, reflecting confidence in their innovative approach to managing autoimmune conditions.
Bears say
Immunovant Inc. focuses on developing IMVT-1402 to treat autoimmune diseases driven by high levels of pathogenic IgG antibodies, but challenges persist in the efficacy of their treatment, with high TRabs levels linked to increased relapse rates. The company's reliance on a single operating segment makes it vulnerable to fluctuations in the market and competitive pressures, limiting its growth capacity. Furthermore, potential complications from TRAbs-mediated TSHR activation may result in severe health risks for patients, affecting the company's credibility and long-term viability in the immunology sector.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares